Cases & Deals

Purdue Pharma successfully resolves Hatch-Waxman claims against companies seeking to make generic version of transdermal patch Butrans®

Clients Purdue Pharma L.P.

Jones Day client Purdue Pharma L.P. successfully resolved a patent infringement action it brought under the Hatch-Waxman Act against two companies that sought FDA approval to market a generic version of Purdue's Butrans® product prior to the expiration of certain patents owned by Purdue. Butrans® is a transdermal patch that delivers buprenorphine, a potent medication used for the treatment of chronic pain.

Purdue Pharma L.P. v. Watson Laboratories, Inc., C.A. No. 14-1227 (D. Del.) (SLR) (SRF)

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.